LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

Inicio・Lista de Acciones・United Therapeutics Corp

United Therapeutics Corp

Cerrado

Sector Salud

373.77 -0.06

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

373.55

Máximo

375.61

Métricas clave
By Trading Economics
Ingresos	31M 309M
Ventas	34M 749M
P/B Media del Sector	16.47 104.138
BPA	6.39
Margen de beneficio	41.274
Empleados	1,168
EBITDA	42M 427M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+6.83 upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	447M 18B
Apertura anterior	373.83
Cierre anterior	373.77

Noticias sobre sentimiento de mercado

By Acuity

91%

12 / 389 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

352.58 / 375.175 Soporte y Resistencia

United Therapeutics Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

7 oct 2024, 15:14 UTC

Principales Movimientos del Mercado

Liquidia Shares Rise After Supreme Court Rejects United Therapeutics' Patent Appeal

Comparación entre iguales

Cambio de precio

United Therapeutics Corp Esperado

Precio Objetivo

By TipRanks

6.83% repunte

Estimación a 12 meses

Media 399.55 USD 6.83%

Máximo 600 USD

Mínimo 302 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para United Therapeutics Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

11 ratings

Comprar

Mantener

Vender

De acuerdo con 11 analistas que ofrecen calificaciones bursátiles a para United Therapeutics Corp Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

352.58 / 375.175Soporte y Resistencia

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

There are no events.

Sentimiento

By Acuity

12 / 389 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de United Therapeutics Corp

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. The Company market and sell four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution, which includes the Tyvaso Inhalation System; Orenitram (treprostinil) Extended-Release Tablets; and Adcirca (tadalafil) Tablets. In the United States, the Company also markets and sells an oncology product, Unituxin (dinutuximab) Injection, which is approved for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion.